Canakinumab - Hyperuricaemia and Gout
You are here : Home > Formulary Search > Canakinumab - Hyperuricaemia and Gout
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
NICE Technology Appraisal
PAD Profile
ChemicalSubstance :
Canakinumab
Indication :
Hyperuricaemia and Gout
Group Name :
Keywords :
Brand Names Include :
Ilaris
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Other Indications
Below are listed other indications that Canakinumab is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Hyperuricaemia and Gout.
Committee Recommendations (1)
NICE is unable to recommend the use in the NHS of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks because no evidence submission was received from the manufacturer of the technology. Canakinumab not currently supported by the Prescribing Clinical Network